Comparison of Visceral Adipokines Visfatin, Vaspin and Omentin Levels in Gestational Diabetes Mellitus Pregnant Women

NCT05463237 | Completed

• 1 other identifier: SiirtUNI
• Study Type: observational
• Target: 174
• Locations: 1 country
• Sites: 1

Brief Summary

The prevalence of maternal obesity is increasing rapidly worldwide and constitutes an important obstetric problem that increases mortality and morbidity in both mothers and infants. Obese women are prone to pregnancy complications such as gestational diabetes mellitus (GDM), and children of obese mothers are more likely to develop cardiovascular and metabolic disease later in life. The risk of developing GDM in obese pregnants is 1.3-3.8 times higher than in pregnant women with a normal body mass index, and approximately 70% of women with GDM remain at risk of developing type 2 diabetes until 28 years postpartum. Gestational diabetes mellitus (GDM) affects approximately 6% of pregnant women and its prevalence is increasing in parallel with the obesity epidemic. GDM is associated with an increased risk of adverse pregnancy outcomes, including macrosomia, preterm delivery, neonatal hypoglycemia, neonatal jaundice, and congenital anomalies. It is also associated with a higher incidence of type 2 diabetes mellitus after birth. It is known that visceral adipose tissue increases in obese women. It is thought that there is a relationship between visceral adipose tissue increase and diabetes. In this study, the levels of new adipocytokines such as Visfatin, Vaspin and Omentin secreted from visceral adipose tissue in patients diagnosed with GDM will be measured.

Conditions

Gestational Diabetes; Obesity; Visceral Obesity

Outcome Measures

Primary Outcomes (1)

• 24-28. Visceral Adipokine Levels in Pregnant Women with Gestational Diabetes Between Weeks

  VASPIN, VISFATIN, OMENTIN levels will be measured in patients with gestational diabetic,

  Between 24-28 weeks of pregnancy, (an average of 6 months)

Study Arms (2)

Pregnant women with gestational diabetes(n:87)

Visceral adipokine level will be examined in pregnant women with gestational diabetes.

Diagnostic Test: oral glucose tolerance test; Diagnostic Test: Blood sample

Control group pregnant (n:87)

Visceral adipokine level will be examined in pregnant women with normal pregnant .

Diagnostic Test: oral glucose tolerance test; Diagnostic Test: Blood sample

Interventions

oral glucose tolerance test DIAGNOSTIC_TEST

oral glucose tolerance test (OGTT) used for the diagnosis of gestational diabetes mellitus between 24-28 weeks of gestation

Control group pregnant (n:87); Pregnant women with gestational diabetes(n:87)

Blood sample DIAGNOSTIC_TEST

Measurement of blood Visfatin, Vaspin and Omentin levels in pregnant women with diabetes

Control group pregnant (n:87); Pregnant women with gestational diabetes(n:87)

Eligibility Criteria

• Age: 18 Years+
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Pregnant women over the age of 18 who are in the first trimester of pregnancy and are not diagnosed with diabetes

You may qualify if:

• \>18 years of age
• At the 2.st trimester of pregnancy

You may not qualify if:

• History of with diabetes mellitus
• Morbidly obese pregnants
• History of abdomen liposuction

Sponsors & Collaborators

• Siirt University: lead

Study Sites (1)

Siirt Üniversity Medical Faculty

Siirt, 56000, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Diabetes, Gestational; Obesity; Obesity, Abdominal

Interventions

Glucose Tolerance Test; Blood Specimen Collection

Condition Hierarchy (Ancestors)

Pregnancy Complications; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Diabetes Mellitus; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases; Endocrine System Diseases; Overweight; Overnutrition; Nutrition Disorders; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Blood Chemical Analysis; Clinical Chemistry Tests; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Diagnostic Techniques, Endocrine; Investigative Techniques; Specimen Handling; Punctures; Surgical Procedures, Operative

Study Officials

• Şerif Aksin, Assoc.Prof

  Siirt University Medical Faculty Obstetrics and Gynecology Departmant

  STUDY DIRECTOR

• Şerif Aksin

  Siirt Üniversity Medical Faculty Obstetrics and Gynecology Department

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: associate professor

Study Record Dates

• First Submitted: June 30, 2022
• First Posted: July 18, 2022
• Study Start: October 31, 2022
• Primary Completion: August 25, 2023
• Study Completion: August 25, 2023
• Last Updated: August 28, 2023

Record last verified: 2023-08

Locations

TU (1)